Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Julphar
Teva
Mallinckrodt
Citi
Cerilliant
Federal Trade Commission
Deloitte
US Army
Healthtrust

Generated: October 22, 2017

DrugPatentWatch Database Preview

LAMICTAL Drug Profile

« Back to Dashboard

What is the patent landscape for Lamictal, and when can generic versions of Lamictal launch?

Lamictal is a drug marketed by Glaxosmithkline Llc and is included in four NDAs. There are five patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in LAMICTAL is lamotrigine. There are thirty-two drug master file entries for this compound. Sixty-seven suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

Summary for Tradename: LAMICTAL

US Patents:0
Applicants:1
NDAs:4
Suppliers / Packagers: see list6
Bulk Api Vendors: see list75
Clinical Trials: see list63
Patent Applications: see list4,555
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:LAMICTAL at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-003May 29, 2009ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-001May 29, 2009ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-004May 29, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-002May 29, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL
lamotrigine
TABLET;ORAL020241-005Dec 27, 1994ABRXYesYes► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL ODT
lamotrigine
TABLET, ORALLY DISINTEGRATING;ORAL022251-002May 8, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL ODT
lamotrigine
TABLET, ORALLY DISINTEGRATING;ORAL022251-004May 8, 2009ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL CD
lamotrigine
TABLET, CHEWABLE;ORAL020764-004Sep 8, 2000ABRXYesNo► Subscribe► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL XR
lamotrigine
TABLET, EXTENDED RELEASE;ORAL022115-006Jun 21, 2011ABRXYesNo► Subscribe► SubscribeY ► Subscribe
Glaxosmithkline Llc
LAMICTAL
lamotrigine
TABLET;ORAL020241-002Dec 27, 1994ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: LAMICTAL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc
LAMICTAL
lamotrigine
TABLET;ORAL020241-003Dec 27, 1994► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL
lamotrigine
TABLET;ORAL020241-005Dec 27, 1994► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL
lamotrigine
TABLET;ORAL020241-001Dec 27, 1994► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL
lamotrigine
TABLET;ORAL020241-002Dec 27, 1994► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL
lamotrigine
TABLET;ORAL020241-004Dec 27, 1994► Subscribe► Subscribe
Glaxosmithkline Llc
LAMICTAL
lamotrigine
TABLET;ORAL020241-006Dec 27, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LAMICTAL

Drugname Dosage Strength RLD Submissiondate
lamotrigineOrally Disintegrating Tablets25 mg, 50 mg, 100 mg, and 200 mgLamictal ODT12/21/2009
lamotrigineExtended-release Tablets25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mgLamictal XR2/12/2014
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
QuintilesIMS
Queensland Health
US Department of Justice
Healthtrust
Express Scripts
Deloitte
Moodys
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot